Serum IL-17 Correlated With Inflammatory Changes in Osteoarthritis and Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
The total number of the included subjects was 120 in 3 equal groups (RA, OA and control). All subject was subjected to serum IL17 level measurement. MSK US (of both wrists, MCPs, PIPs and DIPs) was done to all patients in RA and OA groups. Disease activity was measured by disease activity score (DAS28) for RA patients. Visual analogue scale for pain (VAS) was obtained from patients in RA and OA groups. Functional assessment was done using health assessment questionnaire (HAQ) for RA patients and the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index for OA patients

Official Title
-----------------
Serum IL-17 Correlated With Inflammatory Changes But Not With Bony Changes in Both Hand Osteoarthritis and Rheumatoid Arthritis

Conditions
-----------------
Rheumatoid Arthritis (RA) and Osteoarthritis (OA)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A patient is considered having definite RA if he/she scores at least 6 points in the established classification system A patient is considered having Hand OA if he /she Hand pain, aching, or stiffness plus 3 or 4 of hard tissue enlargement of 2 or more of 10 selected joints or hard tissue enlargement of 2 or more DIP joints or fewer than 3 swollen MCP joints, or deformity of at least 1 of 10 selected joints which are are the second and third distal interphalangeal (DIP), the second and third proximal interphalangeal, and the first carpometacarpal joints of both hands Exclusion Criteria: Any subject with liver diseases, coronary artery diseases, kidney diseases or other inflammatory conditions was excluded from the study.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control group<br>Healthy volunteers with no symptoms or signs of rheumatoid arthritis or osteoarthritis | |
| Rheumatoid arthritis group<br>Rheumatoid arthritis (RA) patients fulfilled 2010 American college of rheumatology (ACR) classification criteria. A patient is considered having definite RA if he/she scores at least 6 points in the established classification system | |
| Osteoarthritis group<br>Osteoarthritis (OA) patients fulfilled 1990 ACR criteria for the classification and reporting of osteoarthritis of the hand. A patient is considered having hand OA if he /she Hand pain, aching, or stiffness plus 3 or 4 of hard tissue enlargement of 2 or more of 10 selected joints or hard tissue enlargement of 2 or more DIP joints or fewer than 3 swollen MCP joints, or deformity of at least 1 of 10 selected joints which are are the second and third distal interphalangeal (DIP), the second and third proximal interphalangeal, and the first carpometacarpal joints of both hands | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical disease activity in Rheumatoid Arthritis (RA) and hand Osteoarthritis (OA) patients | During the whole course of the study, disease activity of the patients was measured by disease activity score (DAS28) for RA patients. Visual analogue scale for pain (VAS) was obtained from patients in RA and OA groups. Functional assessment was done using health assessment questionnaire (HAQ) for RA patients and the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index for OA patients. | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IL-17 serum levels in RA and OA patients | IL-17 will be measured by enzyme linked immunosorbent assay from collected serum samples from the study participants | 2 weeks |